CR20210513A - Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
CR20210513A
CR20210513A CR20210513A CR20210513A CR20210513A CR 20210513 A CR20210513 A CR 20210513A CR 20210513 A CR20210513 A CR 20210513A CR 20210513 A CR20210513 A CR 20210513A CR 20210513 A CR20210513 A CR 20210513A
Authority
CR
Costa Rica
Prior art keywords
pyrazino
hexahydro
treatment
autoimmune disease
pyrazine compounds
Prior art date
Application number
CR20210513A
Other languages
English (en)
Inventor
Hong Shen
Lue Dai
Yongfu Liu
Fabian Dey
Buyu Kou
Zhiwei Zhang
Wei Zhu
Zhisen Zhang
Yafei Liu
Linuo Zhu
Haixia Liu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210513A publication Critical patent/CR20210513A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), A ( ) n (I), en donde R1 a R3 , n y A son como se describen en la presente, y su sal aceptable desde el punto de vista farmacéutico de estos, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
CR20210513A 2019-04-09 2020-04-07 Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria CR20210513A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019081900 2019-04-09
CN2019121598 2019-11-28
CN2020078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
CR20210513A true CR20210513A (es) 2021-11-02

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210513A CR20210513A (es) 2019-04-09 2020-04-07 Compuestos de haxahidro 1-h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Country Status (19)

Country Link
US (1) US20220340597A1 (es)
EP (1) EP3953356B1 (es)
JP (1) JP7692838B2 (es)
KR (1) KR20210149163A (es)
CN (1) CN113710672B (es)
AU (1) AU2020272467A1 (es)
BR (1) BR112021020297A2 (es)
CA (1) CA3135129A1 (es)
CL (1) CL2021002621A1 (es)
CO (1) CO2021013166A2 (es)
CR (1) CR20210513A (es)
IL (1) IL286870A (es)
MA (1) MA55594A (es)
MX (1) MX2021012223A (es)
PE (1) PE20212178A1 (es)
PH (1) PH12021552533A1 (es)
SG (1) SG11202110401WA (es)
TW (1) TW202104230A (es)
WO (1) WO2020207991A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114599652B (zh) * 2019-10-31 2024-07-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物
WO2021094301A1 (en) * 2019-11-12 2021-05-20 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease
EP4061816A1 (en) 2019-11-19 2022-09-28 F. Hoffmann-La Roche AG Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
US12478621B2 (en) 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN114761406B (zh) 2019-12-03 2024-04-19 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物
JP2023533807A (ja) * 2020-07-14 2023-08-04 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2663555T3 (en) * 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
HRP20171981T1 (hr) 2012-09-14 2018-02-09 F. Hoffmann - La Roche Ag Derivati pirazolkarboksamida kao taar modulatora za uporabu u liječenju nekoliko poremećaja poput depresije, dijabetesa i parkinsonove bolesti
US9643967B2 (en) * 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
JP2021527100A (ja) * 2018-06-13 2021-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物

Also Published As

Publication number Publication date
AU2020272467A1 (en) 2021-10-14
WO2020207991A1 (en) 2020-10-15
PH12021552533A1 (en) 2022-06-20
PE20212178A1 (es) 2021-11-09
EP3953356C0 (en) 2023-07-26
EP3953356B1 (en) 2023-07-26
CO2021013166A2 (es) 2021-12-10
SG11202110401WA (en) 2021-10-28
BR112021020297A2 (pt) 2021-12-14
CN113710672A (zh) 2021-11-26
IL286870A (en) 2021-10-31
EP3953356A1 (en) 2022-02-16
JP7692838B2 (ja) 2025-06-16
CN113710672B (zh) 2025-01-03
MA55594A (fr) 2022-02-16
MX2021012223A (es) 2021-11-03
CA3135129A1 (en) 2020-10-15
TW202104230A (zh) 2021-02-01
KR20210149163A (ko) 2021-12-08
JP2022527588A (ja) 2022-06-02
CL2021002621A1 (es) 2022-05-13
US20220340597A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
MX2022008066A (es) Compuestos triciclicos sustituidos.
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CR20240312A (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias
EP4566612A3 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
PH12022551523A1 (en) Cyclic compounds and methods of using same
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2026000537A (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
PH12021552513A1 (en) Pyrrole compounds
MX2021007247A (es) Derivados de rapamicina.
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
MX394882B (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
MX2025010256A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12021552953A1 (en) Tricyclic compounds
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida